Sanofi A/S: Financial statements 2025
CVR: 19064301
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Sanofi A/S (CVR 19064301) has filed annual accounts for 2025. In 2025, the company reported revenue of DKK 442,343,000 and a net result of DKK 5,043,000 compared with DKK 6,217,000 the year before. That is a decrease of 2.3% compared with the year before. The profit margin was 1.1%. Equity in the 2025 report amounted to DKK 58,663,000. The solvency ratio was 25.2%. The company had 78,000 employees in the financial year.
- Revenue
- DKK 442,343,000
- Gross Profit
- DKK 100,902,000
- Profit/Loss
- DKK 5,043,000
- Equity
- DKK 58,663,000
- Total Assets
- DKK 232,819,000
- Employees
- 78,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 442.3 mio. | 100.9 mio. | 5 mio. | 58.7 mio. | 78000 |
| 2024 | 452.6 mio. | 107.1 mio. | 6.2 mio. | 53.6 mio. | 81 |
| 2023 | 527.6 mio. | 102.5 mio. | 3.7 mio. | 47.4 mio. | 83 |
| 2022 | 530.9 mio. | 115 mio. | 15.9 mio. | 43.7 mio. | 85 |
| 2021 | 591.1 mio. | 135.7 mio. | 22 mio. | 69.3 mio. | 86 |
Official annual report
How creditworthy is Sanofi A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Sanofi A/S has won the tender "Amgros 2026 1.615.b" issued by Amgros I/S worth 48,195,968 DKK.
Sanofi A/S has won the tender "Amgros 2026 2.290.b" issued by Amgros I/S worth 88,050,546 DKK.
Sanofi A/S has won the tender "Amgros 2026 1.604.a" issued by Amgros I/S worth 501,367,776 DKK.
Sanofi A/S has won the tender "Amgros 2026 2.210.a" issued by Amgros I/S worth 102,909,186 DKK.
Sanofi A/S has won the tender "Amgros 2026 1.702.b" issued by Amgros I/S worth 22,987,384 DKK.
Sanofi A/S has won the tender "Udbud af rammekontrakter vedr. rabiesvacciner og TBE-vacciner" issued by Statens Serum Institut worth 1 DKK.
Sanofi A/S has won the tender "Amgros 2026 1.966.a" issued by Amgros I/S worth 840,000,000 DKK.
Sanofi A/S has published its annual report for 2024. Revenue came to DKK 452,617,000, and the net result was DKK 6,217,000.
Sanofi A/S has won the tender "Rammeaftale om køb af Xenpozyme (olipudase alfa)" issued by Amgros I/S worth 14,000,000 DKK.
Sanofi A/S has won the tender "Amgros 2025 1.713.a" issued by Amgros I/S worth 861,000 DKK.
About Sanofi A/S
Sanofi A/S is a Danish company of the type Aktieselskab based in København Ø, founded in 1996. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named SANOFI-AVENTIS DENMARK A/S and AVENTIS PHARMA A/S. The management consists of Odd Arne Gabriel Johannessen. The board consists of Birgitte Fyhn (chair), Hao Zheng and Odd Arne Gabriel Johannessen. The company is owned by Sanofi-Aventis Participations. The company has 87 employees (2026). In 2025, the company reported revenue of DKK 442,343,000 and a net result of DKK 5,043,000 compared with DKK 6,217,000 the year before. Equity in the 2025 report amounted to DKK 58,663,000.